Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism

References

• Department of Health U, Services H, for Disease Control C, et al. Smoking Cessation: A Report of the Surgeon General. 2020.
   Google Scholar
• Hughes JR, Keely J, Naud S Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29–38.
   Google Scholar
• Steinberg MB, Akincigil A, Delnevo CD, et al. Gender and age disparities for smoking-cessation treatment. Am J Prev Med. 2006;30(5):405–412.
   PubMed Web of Science ®Google Scholar
• Silagy C, Lancaster T, LF S, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2004;3:1–123.
   Google Scholar
• Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685–691.
   PubMed Web of Science ®Google Scholar
• Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst. Rev. 2013;
   Google Scholar
• Posselt WR. “Chemische Untersuchung des Tabaks und Darstellung eines eigenthümlich wirksamen Prinzips dieser Pflanze” [Chemical investigation of tobacco and preparation of a characteristically active constituent of this plant]. Mag für Pharm. 1828;6:138–161.
   Google Scholar
• Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med. 2008;121(4):S3–S10.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Porchet H, Sheiner L, et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther. 1988;44(1):23–28.
   PubMed Web of Science ®Google Scholar
• Armitage AKTD, TURNER DM. Absorption of nicotine cigarette and cigar smoke though the oral mucosa. Nature. 1970;226(5252):1231–1232.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, PJ III. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther. 1984;35(4):499–504.
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Nicotine and smokeless tobacco. CA Cancer J Clin. 1988;38(4):244–247.
   PubMed Web of Science ®Google Scholar
• Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 1996;16(5):905–908.
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol. 1996;36(1):597–613.
   PubMedGoogle Scholar
• Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci. 2006;27(9):482–491.
   PubMed Web of Science ®Google Scholar
• Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci. 2004;25(6):317–324.
   PubMed Web of Science ®Google Scholar
• Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001;70(4):439–446.
   PubMed Web of Science ®Google Scholar
• Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000;27(2):349–357.
   PubMed Web of Science ®Google Scholar
• Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol. 2000;393(1–3):295–314.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Schwartz RS. Nicotine addiction. N Engl J Med. 2010;362(24):2295.
   PubMed Web of Science ®Google Scholar
• Paradiso K, Brehm P. Long-term desensitization of nicotinic acetylcholine receptors is regulated via protein kinase A-mediated phosphorylation. J Neurosci. 1998;18(22):9227–9237.
   PubMed Web of Science ®Google Scholar
• Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Rev. 2005;48(3):420–437.
   PubMedGoogle Scholar
• Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006;63(8):907–915.
   PubMed Web of Science ®Google Scholar
• Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40(5):616–622.
   PubMed Web of Science ®Google Scholar
• Fowler CD, Lu Q, Johnson PM, et al. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature. 2011;471(7340):597–601.
   PubMed Web of Science ®Google Scholar
• Thorgeirsson TE, Geller F, Sulem P, et al., KS. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638–642.
   PubMed Web of Science ®Google Scholar
• Falcone M, Cao W, Bernardo L, et al. Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate. Biol Psychiatry. 2016 Aug 1;80(3):190–7. doi:10.1016/j.biopsych.2015.11.015. Epub 2015 Nov 26. PMID: 26805583; PMCID: PMC5625335
   Google Scholar
• Dubroff JG, Doot RK, Falcone M, et al. Decreased nicotinic receptor availability in smokers with slow rates of nicotine metabolism. J Nucl Med. 2015;56(11):1724–1729.
   PubMed Web of Science ®Google Scholar
• Tang DW, Hello B, Mroziewicz M, et al. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. Neuroimage. 2012;60(4):2136–2143.
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Herman AI, Nadim H, et al. Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology. 2012;37(6):1509–1516.
   PubMed Web of Science ®Google Scholar
• Munafò MR, Johnstone EC, Walther D, et al. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res. 2011;13(10):982–988.
   PubMed Web of Science ®Google Scholar
• Munafò MR, Timofeeva MN, Morris RW, et al. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. Rev. | JNCI. 2012;104:740–748.
   Google Scholar
• Bierut LJ, Dependence N. Genetic Variation in the Nicotinic Receptors. Drug Alcohol Depend. 2009;1:64–69.
   Google Scholar
• Sarginson JE, Killen JD, Lazzeroni LC, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet Part B Neuropsychiatr Genet. 2011;156(3):275–284.
   Google Scholar
• Kuryatov A, Berrettini W, Lindstrom J. Acetylcholine receptor (AChR) α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2) 2α5 AChR function. Mol Pharmacol. 2011;79(1):119–125.
   PubMed Web of Science ®Google Scholar
• Furberg H, Kim Y, Dackor J, et al. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42:441–447.
   PubMed Web of Science ®Google Scholar
• Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16(1):36–49.
   PubMed Web of Science ®Google Scholar
• Chen LS, Hung RJ, Baker T, et al. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis-a meta-analysis. J Natl Cancer Inst. 2015;107(5):1–9.
   Google Scholar
• Chen L-S, Saccone NL, Culverhouse RC, et al. Smoking and genetic risk variation across populations of european, asian, and african-american ancestry-a meta-analysis of chromosome 15q25 NIH public access author manuscript. Genet Epidemiol. 2012;36(4):340–351.
   PubMed Web of Science ®Google Scholar
• Berrettini W, Yuan X, Tozzi F, et al. α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008;13(4):368–373.
   PubMed Web of Science ®Google Scholar
• David SP, Hamidovic A, Chen GK, et al. Genome-wide meta-analyses of smoking behaviors in african americans. Transl. Psychiatry. 2012;2.
   Google Scholar
• Wang JC, Cruchaga C, Saccone NL, et al. Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet. 2009;18(16):3125–3135.
   PubMed Web of Science ®Google Scholar
• Saccone NL, Culverhouse RC, Schwantes-An TH, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: A meta-analysis and comparison with lung cancer and COPD. PLoS Genet. 2010;6(8):1–16.
   Web of Science ®Google Scholar
• Bierut LJ, Madden PAF, Breslau N, et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet. 2007;16(1):24–35.
   PubMed Web of Science ®Google Scholar
• Liu QR, Drgon T, Walther D, et al. Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc Natl Acad Sci U S A. 2005;102(33):11864–11869.
   PubMed Web of Science ®Google Scholar
• Pérez-Rubio G, Pérez-Rodríguez ME, Fernández-López JC, et al. SNPs in NRXN1 and CHRNA5 are associated to smoking and regulation of GABAergic and glutamatergic pathways. Pharmacogenomics. 2016;17(10):1145–1158.
   PubMed Web of Science ®Google Scholar
• Docampo E, Ribasés M, Gratacòs M, et al. Association of neurexin 3 polymorphisms with smoking behavior. Genes, Brain Behav. 2012;11(6):704–711.
   PubMed Web of Science ®Google Scholar
• Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry. 2004;61(11):1107–1115.
   PubMed Web of Science ®Google Scholar
• Zuckerman M. Sensation seeking: A comparative approach to a human trait. Behav Brain Sci. 1984;7(3):413–434.
   Web of Science ®Google Scholar
• Mitchell SH. Measures of impulsivity in cigarette smokers and non-smokers. Psychopharmacology (Berl). 1999;146(4):455–464.
   PubMed Web of Science ®Google Scholar
• West R, Mcneill A, Raw M. Smoking cessation update Smoking cessation guidelines for health professionals: an update. Thorax. 2000;55(12):987–999.
   PubMed Web of Science ®Google Scholar
• Fiore MC, Jaén CR, Baker TB et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service Report. Am. J. Prev. Med. 2008;35:158–176.
   Google Scholar
• Scherman A, Tolosa JE, McEvoy C, Ashley Scherman JET and CM. Smoking cessation in pregnancy: a continuing challenge in the United States. Ther Adv Drug Saf. 2018;9(8):457–474.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug approval package: nicorette (nicotine polacrilex gum) NDA# 18-612/S25 & 20-066/S7 [Internet]. 1998 [ cited 2020 Apr 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18-612s025_Nicorette.cfm.
   Google Scholar
• Cole PV, Feyerabend C, Cole PV. Plasma nicotine levels after cigarette smoking and chewing nicotine gum. Br Med J. 1976;1(6017):1043–1046.
   PubMedGoogle Scholar
• Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst. Rev. John Wiley and Sons Ltd; 2018.
   Google Scholar
• Cooper BR, Wang CM, Cox RF, et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (wellbutrin®) are mediated by a noradrenergic mechanism. Neuropsychopharmacology. 1994;11(2):133–141.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug approval package: zyban (bupropion hydrochloride) NDA# 020711s002/s004 [Internet]. 1997 [ cited 2020 Apr 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020711_s002s004_ZybanTOC.cfm.
   Google Scholar
• Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17): 1995–1202. DOI:10.1056/NEJM199710233371703
   PubMed Web of Science ®Google Scholar
• Aubin H-J. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs. 2002;62(Supplement 2):45–52.
   PubMedGoogle Scholar
• Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an r42 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474–3477.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug approval package: chantix (varenicline) NDA #021928 [Internet]. 2006 [ cited 2020 Apr 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021928_s000_chantixtoc.cfm.
   Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation a randomized controlled trial. J Am Med Assoc. 2006;296(1):56–63.
   PubMed Web of Science ®Google Scholar
• Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166(15):1571–1577.
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. J Am Med Assoc. 2006;296(1):47–55.
   PubMed Web of Science ®Google Scholar
• Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database. BMJ. 2009;339(oct01 1):1–7.
   Google Scholar
• DP K, Paciga S, Pickering E, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012;37(3):641–650.
   PubMed Web of Science ®Google Scholar
• Bauld L, Bell K, McCullough L, et al. The effectiveness of NHS smoking cessation services: A systematic review. J Public Health (Bangkok). 2010;32(1):71–82.
   PubMed Web of Science ®Google Scholar
• Quaak M, Van Schayck CP, Knaapen AM, et al. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur Respir J. 2009;33(3):468–480.
   PubMed Web of Science ®Google Scholar
• Bough KJ, Lerman C, Rose JE, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther. 2013;93(6):526–538.
   PubMed Web of Science ®Google Scholar
• Quaak M, Van Schooten FJ, Van Schayck CP. Pharmacogenetics of smoking: how far to the clinic? Pharmacogenomics. 2014;15(6):723–726.
   PubMed Web of Science ®Google Scholar
• Xian H, Scherrer JF, Madden PAF, et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. PubMed Nicotine Tob Res. 2003;5(2):245–254.
   PubMed Web of Science ®Google Scholar
• Schuit E, Panagiotou OA, Munafò MR, et al. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. Cochrane Database Syst Rev. 2017;9:1–321.
   Google Scholar
• Chen L-S, Baker TB, Piper ME, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry. 2012;169(7):735–742.
   PubMed Web of Science ®Google Scholar
• Bergen AW, Javitz HS, Krasnow R, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics. 2013;23(2):94–103.
   PubMed Web of Science ®Google Scholar
• Lerman C, Schnoll RA, Hawk LW, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: A randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2):131–138.
   PubMed Web of Science ®Google Scholar
• Patterson F, Schnoll RA, Wileyto EP, et al. Toward personalized therapy for smoking cessation: A randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther. 2008;84(3):320–325.
   PubMed Web of Science ®Google Scholar
• Schnoll RA, Patterson F, Wileyto EP, et al. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study. Pharmacol Biochem Behav. 2009;92(1):6–11.
   PubMed Web of Science ®Google Scholar
• Dale LC, Glover ED, Sachs DPL, et al. Bupropion for smoking cessation: predictors of successful outcome. Chest. 2001;119(5):1357–1364.
   PubMed Web of Science ®Google Scholar
• Lerman C, Jepson C, Wileyto EP, et al. Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology. 2006;31(1):231–242.
   PubMed Web of Science ®Google Scholar
• Lerman C, Wileyto EP, Audrain J, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Heal Psychol. 2003;22(5):541–548.
   PubMed Web of Science ®Google Scholar
• Swan GE, Jack LM, Valdes AM, et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Heal Psychol. 2007;26(3):361–368.
   PubMed Web of Science ®Google Scholar
• O’Gara C, Stapleton J, Sutherland G, et al. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics. 2007;17(1):61–67.
   PubMed Web of Science ®Google Scholar
• Berrettini WH, Wileyto EP, Epstein L, et al. Catechol-O-Methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry. 2007;61(1):111–118.
   PubMed Web of Science ®Google Scholar
• Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. DRUG Metab Dispos Drug Metab Dispos. 2000;28:1222–1230.
   PubMed Web of Science ®Google Scholar
• Claw KG, Beans JA, Lee S-B, et al. Pharmacogenomics of nicotine metabolism: novel CYP2A6 and CYP2B6 genetic variation patterns in alaska native and american indian populations. Nicotine Tob Res. 2019;22(6):910–918.
   Web of Science ®Google Scholar
• Kharasch ED, Crafford A. Common polymorphisms of CYP2B6 influence stereoselective bupropion disposition. Clin Pharmacol Ther. 2019;105(1):142–152.
   PubMed Web of Science ®Google Scholar
• Hesse LM, He P, Krishnaswamy S, et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics. 2004;14(4):225–238.
   PubMedGoogle Scholar
• Benowitz NL, Zhu AZXX, Tyndale RF, et al. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics. 2013;23(3):135–141.
   PubMed Web of Science ®Google Scholar
• Lee AM, Jepson C, Hoffmann E, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry. 2007;62(6):635–641.
   PubMed Web of Science ®Google Scholar
• Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5):448–453.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;13(10):619–626.
   PubMedGoogle Scholar
• Zhu AZX, Cox LS, Nollen N, et al. CYP2B6 and bupropion s smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther. 2012;92(6):771–777.
   PubMed Web of Science ®Google Scholar
• Lerman C, Shields PG, Wileyto EP, et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 2002;12(8):627–634.
   PubMedGoogle Scholar
• Zhu AZX, Zhou Q, Cox LS, et al. Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab Dispos. 2014;42(11):1971–1977.
   PubMedGoogle Scholar
• Connarn JN, Flowers S, Kelly M, et al. Pharmacokinetics and pharmacogenomics of bupropion in three different formulations with different release kinetics in healthy human volunteers. Aaps J. 2017;19(5):1513–1522.
   PubMed Web of Science ®Google Scholar
• Gufford BT, Lu JBL, Metzger IF, et al. Stereoselective glucuronidation of bupropion metabolites in vitro and in vivo. Drug Metab Dispos. 2016;44(4):544–553.
   PubMed Web of Science ®Google Scholar
• Gault J, Robinson M, Berger R, et al. Genomic organization and partial duplication of the human α7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics. 1998;52(2):173–185.
   PubMed Web of Science ®Google Scholar
• Cameli C, Bacchelli E, De Paola M, et al. Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment. Eur J Hum Genet. 2018;26(12):1824–1831.
   PubMed Web of Science ®Google Scholar
• Scott Obach R, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34(1):121–130.
   PubMed Web of Science ®Google Scholar
• Glatard A, Guidi M, Dobrinas M, et al. Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. Eur J Clin Pharmacol. 2019;75(7):939–949.
   PubMed Web of Science ®Google Scholar
• Feng B, Obach R, Burstein A, et al. Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: an In Vitro–In Vivo Study. Clin Pharmacol Ther. 2008;83(4):567–576.
   PubMed Web of Science ®Google Scholar
• Faessel HM, Obach RS, Rollema H, et al. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin. Pharmacokinet. Springer; Sep 30, 2010 p. 799–816.
   Google Scholar
• Bergen AW, Javitz HS, Krasnow R, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine Tob Res. 2014;16(12):1638–1646.
   PubMed Web of Science ®Google Scholar
• Rocha Santos J, Tomaz PRX, Issa JS, et al. CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy. Front Genet. 2015;6:1–7.
   PubMed Web of Science ®Google Scholar
• Saccone NL, Saccone SF, Hinrichs AL, et al. Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am J Med Genet Part B Neuropsychiatr Genet. 2009;150(4):453–466.
   Web of Science ®Google Scholar
• Pianezza ML, Sellers EM, Tyndale RF, RFT. Nicotine metabolism defect reduces smoking. Nature. 1998;393(6687):750.
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Nicotine addiction. Prim Care - Clin Off Pract. 1999;26:611–631.
   PubMed Web of Science ®Google Scholar
• Perez-Paramo YX, Chen G, Ashmore JH, et al. Nicotine-N’-oxidation by flavin monooxygenase enzymes. Cancer Epidemiol Biomarkers Prev. 2019;28(2):311–320.
   PubMed Web of Science ®Google Scholar
• Park SB, Jacob P, Benowitz NL, et al. Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1ʹ-oxide. Chem Res Toxicol. 1993;6(6):880–888.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yoshihiko T, Noriaki K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos. 1996;24(11):1212–1217.
   PubMed Web of Science ®Google Scholar
• Cashman JR, Park SB, Yang ZC, et al. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N’-oxide. Chem Res Toxicol. 1992;5(5):639–646.
   PubMed Web of Science ®Google Scholar
• Hecht SS, Hochalter BJ, Villalta PW, et al. 2ʹ-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc Natl Acad Sci U S A. 2000;97(23):12493–12497.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Nakajima M, Fukami T, et al. CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos. 2005;33(12):1811–1818.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yamamoto T, Nunoya K-I, et al. Characterization of CYP2A6 Involved in 3ʹ-hydroxylation of cotinine in human liver microsomes. Pharmacol Exp Ther. 1996;277:1010–1015.
   PubMed Web of Science ®Google Scholar
• Murphy SE, Johnson LM, Pullo DA. Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chem Res Toxicol. 1999;12(7):639–645.
   PubMed Web of Science ®Google Scholar
• Kuehl GE, Murphy SE. N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2003;31(11):1361–1368.
   PubMed Web of Science ®Google Scholar
• Kaivosaari S, Toivonen PI, LM H, et al. nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol. 2007;72(3):761–768.
   PubMed Web of Science ®Google Scholar
• Chen G, Blevins-Primeau AS, Dellinger RW, et al. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp > Tyr) polymorphism function by the UGT2B10 Codon 67 (Asp > Tyr) polymorphism. Cancer Res. 2007;67(19):9024–9029.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Tanaka E, Kwon JT, et al. Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug Metab Dispos. 2002;30(12):1484–1490.
   PubMed Web of Science ®Google Scholar
• Chen G, Giambrone NE, Lazarus P. Glucuronidation of trans-3ʹ-hydroxycotinine by UGT2B17 and UGT2B10. Pharmacogenet Genomics. 2012;22(3):183–190.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Nakajima M, Katoh M, et al. Trans-3′-hydroxycotinine O- and N-glucuronidations in human liver microsomes. Drug Metab Dispos. 2005;33(1):23–30.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Jacob P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther. 1994;56(5):483–493.
   PubMed Web of Science ®Google Scholar
• Kandel DB, Hu M-C, Schaffran C, et al. Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am J Epidemiol. 2007;165(8):901–910.
   PubMed Web of Science ®Google Scholar
• Swan GE, Lessov-Schlaggar CN, Bergen AW, et al. Genetic and environmental influences on the ratio of 3 ’ hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics. 2009;19(5):388–398.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Kuroiwa Y, Yokoi T. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev. 2002;34(4):865–877.
   PubMed Web of Science ®Google Scholar
• Rangiah K, Hwang W-T, Mesaros C, et al. Nicotine exposure and metabolizer phenotypes from ana lysis of urinary nicotine and its 15 metabolites by LC–MS. Bioanalysis. 2011;3(7):745–761.
   PubMed Web of Science ®Google Scholar
• Murphy SE, Park SSL, Thompson EF, et al. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups. Carcinogenesis. 2014;35(11):2526–2533.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yokoi T. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet. 2005;20(4):227–235.
   PubMedGoogle Scholar
• Yamanaka H, Nakajima M, Nishimura K, et al. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci. 2004;22(5):419–425.
   PubMed Web of Science ®Google Scholar
• SE M. Nicotine metabolism and smoking: ethnic differences in the role of P450 2A6. Chem Res Toxicol. 2017;30(1):410–419.
   PubMed Web of Science ®Google Scholar
• Murphy SE, Sipe CJ, Choi K, et al. Low cotinine glucuronidation results in higher serum and saliva cotinine in african american compared to white smokers. Cancer Epidemiol Biomarkers Prev. 2017;26(7):1093–1099.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Pomerleau OF, Pomerleau CS, et al. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res. 2003;5(5):621–624.
   PubMed Web of Science ®Google Scholar
• Dempsey D, Tutka P, Iii PJ, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;450(1):64–72.
   Google Scholar
• Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol. 2006;30(6):386–389.
   PubMed Web of Science ®Google Scholar
• St Helen G, Jacob P, Benowitz NL. Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. Nicotine Tob Res. 2013;15(11):1939–1942.
   PubMed Web of Science ®Google Scholar
• St.Helen G, Novalen M, Heitjan DF, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1105–1114.
   PubMed Web of Science ®Google Scholar
• Ashare RL, Thompson M, Leone F, et al. Differences in the rate of nicotine metabolism among smokers with and without HIV. AIDS. 2019;33(6):1083–1088.
   PubMed Web of Science ®Google Scholar
• Wells QS, Freiberg MS, Greevy RA, et al. Nicotine metabolism-informed care for smoking cessation: A pilot precision RCT. Nicotine Tob Res. 2018;20(12):1489–1496.
   PubMed Web of Science ®Google Scholar
• Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79(6):600–608.
   PubMed Web of Science ®Google Scholar
• Kaufmann A, Hitsman B, Goelz PM, et al. Addictive behaviors rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. Addict Behav. 2015;51:93–99.
   PubMedGoogle Scholar
• Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in african-american light smokers. Clin Pharmacol Ther. 2009;85(6):635–643.
   PubMed Web of Science ®Google Scholar
• Shahab L, Bauld L, McNeill A, et al. Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study. Addiction. 2019;114(2):304–314.
   PubMed Web of Science ®Google Scholar
• Verplaetse TL, MacKenzie RP, Roberts W, et al. associations between nicotine metabolite ratio and gender with transitions in cigarette smoking status and E-cigarette use: findings across waves 1 and 2 of the population assessment of tobacco and health (PATH) study. Nicotine Tob Res. 2020;22(8):1316–1321.
   PubMed Web of Science ®Google Scholar
• West O, Hajek P, Mcrobbie H, et al. Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. Psychopharmacology (Berl). 2011;218(2):313–322.
   PubMed Web of Science ®Google Scholar
• Johnstone E, Benowitz N, Cargill A, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther. 2006;80(4):319–330.
   PubMed Web of Science ®Google Scholar
• Shahab L, Mortimer E, Bauld L, et al. Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of stop smoking services in England. Sci Rep. 2017;7(1):1–9.
   PubMedGoogle Scholar
• B V F, O’Connor RJ, Benowitz N, et al. Nicotine Metabolite Ratio (NMR) prospectively predicts smoking relapse: longitudinal findings from ITC surveys in five countries. Nicotine Tob Res. 2017;19(9):1040–1047.
   PubMed Web of Science ®Google Scholar
• Xue Y, Sun D, Daly A, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet. 2008;83(3):337–346.
   PubMed Web of Science ®Google Scholar
• Zhu AZX, Zhou Q, Cox LS, et al. Variation in trans-3ʹ-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. PLoS One. 2013;8:1–7.
   Web of Science ®Google Scholar
• Chenoweth MJ, Novalen M, Jr LWH, et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1773–1782.
   PubMed Web of Science ®Google Scholar
• Benowitz N, Lessovschlaggar C, Swan G, et al. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. 2006;79(5):480–488.
   PubMed Web of Science ®Google Scholar
• Higashi E, Fukami T, Itoh M, et al. Human CYP2A6 Is Induced by estrogen via estrogen receptor. DRUG Metab Dispos Drug Metab Dispos. 2007;35(10):1935–1941.
   PubMed Web of Science ®Google Scholar
• Mwenifumbo JC, Sellers EM, Tyndale RF. Nicotine metabolism and CYP2A6 activity in a population of black african descent: impact of gender and light smoking. Drug Alcohol Depend. 2007;89(1):24–33.
   PubMed Web of Science ®Google Scholar
• Bowker K, Lewis S, Coleman T, et al. Changes in the rate of nicotine metabolism across pregnancy: A longitudinal study. Addiction. 2015;110(11):1827–1832.
   PubMed Web of Science ®Google Scholar
• Allenby CE, Boylan KA, Lerman C,,, et al. Precision medicine for tobacco dependence: development and validation of the nicotine metabolite ratio. J Neuroimmune Pharmacol. 2016;11(3):471–483.
   PubMed Web of Science ®Google Scholar
• Mooney ME, Li -Z-Z, Murphy SE, et al. Stability of the Nicotine Metabolite Ratio in ad Libitum and Reducing Smokers. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1396–1400.
   PubMed Web of Science ®Google Scholar
• MacDougall JM, Fandrick K, Zhang X, et al. Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues. Chem Res Toxicol. 2003;16(8):988–993.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Herrera B, Jacob P. Mentholated cigarette smoking inhibits nicotine metabolism. J Pharmacol Exp Ther. 2004;310(3):1208–1215.
   PubMed Web of Science ®Google Scholar
• Strasser AA, Benowitz NL, Pinto AG, et al. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev. 2011;20(2):234–238.
   PubMed Web of Science ®Google Scholar
• Gaedigk et al. 2018 CPT 103:399; Gaedigk et al. 2019, CPT 105:29 et al. Pharmacogene Variation Consortium (PharmVar) at www.PharmVar.org. [ cited 2020 Nov 18]. Available from: https://www.pharmvar.org/.
   Google Scholar
• Bloom J, Hinrichs AL, Wang JC, et al. the contribution of common CYP2A6 alleles to variation in nicotine metabolism among european americans. Pharmacogenet Genomics. 2012;21(7):403–416.
   Web of Science ®Google Scholar
• Bloom AJ, Harari O, Martinez M, et al. A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele. Pharmacogenet Genomics. 2013;23(3):107–116.
   PubMed Web of Science ®Google Scholar
• Yuan J-M-M, Nelson HH, Carmella SG, et al. CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the singapore chinese health study. Carcinogenesis. 2017;38(4):411–418.
   PubMed Web of Science ®Google Scholar
• Yuan J-M-M, Nelson HH, Butler LM, et al. Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study. Int J Cancer. 2016;138(9):2161–2171.
   PubMed Web of Science ®Google Scholar
• Pérez-Rubio G, López-Flores LA, Ramírez-Venegas A, et al. Genetic polymorphisms in CYP2A6 are associated with a risk of cigarette smoking and predispose to smoking at younger ages. Gene. 2017;628:205–210.
   PubMed Web of Science ®Google Scholar
• Verde Z, Santiago C, JMR G-M, et al. “Smoking Genes”: A genetic association study. PLoS One. 2011;6(10):3–8.
   Web of Science ®Google Scholar
• Minematsu N, Nakamura H, Furuuchi M, et al. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur Respir J. 2006;27(2):289–292.
   PubMed Web of Science ®Google Scholar
• Xu C, Rao YS, Xu B, et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun. 2002;290(1):318–324.
   PubMed Web of Science ®Google Scholar
• Pitarque M, Von Richter O, Oke B, et al. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun. 2001;284(2):455–460.
   PubMed Web of Science ®Google Scholar
• Yoshida R, Nakajima M, Nishimura K, et al. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther. 2003;74(1):69–76.
   PubMed Web of Science ®Google Scholar
• Oscarson M, McLellan RA, Asp V, et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat. 2002;20(4):275–283.
   PubMed Web of Science ®Google Scholar
• Borrego-Soto G, Perez-Paramo YX, Chen G, et al. Genetic variants in CYP2A6 and UGT1A9 genes associated with urinary nicotine metabolites in young mexican smokers. Pharmacogenomics J. 2020;20(4):586–594.
   PubMed Web of Science ®Google Scholar
• Piliguian M, Zhu AZX, Zhou Q, et al. Novel CYP2A6 variants identified in african americans are associated with slow nicotine metabolism in vitro and in vivo. Pharmacogenet Genomics. 2014;24(2):118–128.
   PubMed Web of Science ®Google Scholar
• Chenoweth MJ, Ware JJ, Zhu AZX, et al. Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. Addiction. 2018;113:509–523.
   Google Scholar
• Fukami T, Nakajima M, Yoshida R, et al. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther. 2004;76(6):519–527.
   PubMed Web of Science ®Google Scholar
• Ho MK, Mwenifumbo JC, Zhao B, et al. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of black-african descent. Pharmacogenet Genomics. 2008;18(1):67–75.
   PubMed Web of Science ®Google Scholar
• Al Koudsi N, Ahluwalia JS, Lin S-K, et al. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J. 2009;9(4):274–282.
   PubMed Web of Science ®Google Scholar
• Baurley JW, Edlund CK, Pardamean CI, et al. Genome-wide association of the laboratory- based nicotine metabolite ratio in three ancestries. Nicotine Tob Res. 2016;18(9):1837–1844.
   PubMed Web of Science ®Google Scholar
• Patel YM, Park SL, Han Y,,, et al. Novel association of genetic markers affecting CYP2A6 activity and lung cancer risk. Cancer Res. 2016;76(19):5768–5776.
   PubMed Web of Science ®Google Scholar
• Loukola A, Buchwald J, Gupta R, et al. A genome-wide association study of a biomarker of nicotine metabolism. PLoS Genet. 2015;11(9):1–23.
   Web of Science ®Google Scholar
• Buchwald J, Chenoweth MJ, Palviainen T, et al. Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. Mol. Psychiatry. 2020;
   Google Scholar
• Al Koudsi N, Tyndale RF. Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica. 2010;40(6):381–392.
   PubMed Web of Science ®Google Scholar
• Dicke KE, Skrlin SM, Murphy SE. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005;33(12):1760–1764.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Hashimoto M, et al. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999;73(2):65–70.
   PubMed Web of Science ®Google Scholar
• Bloom AJ, Martinez M, Chen LS, et al. CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes. PLoS One. 2013;8(11):1–13.
   Web of Science ®Google Scholar
• HZ R, AM V, DM N, et al. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenet Genomics. 2007;17(12):1007–1015.
   PubMed Web of Science ®Google Scholar
• Bloom AJ, Wang PF, Kharasch ED. Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes. Pharmacol Res Perspect. 2019;7(2):1–8.
   Web of Science ®Google Scholar
• Taghavi T, Gideon SH, Benowitz NL, RFT. Effect of UGT2B10, UGT2B17, FMO3, and OCT2 Genetic Variation on Nicotine and Cotinine Pharmacokinetics and Smoking in African Americans. Pharmacogenet Genomics. 2017;20:48–55.
   Google Scholar
• Chenoweth MJ, Zhu AZX, Sanderson L, et al. Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO) −3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. Pharmacogenet Genomics. 2013;24(3):172–176.
   Web of Science ®Google Scholar
• Bushueva O, Solodilova M, Churnosov M, et al. the flavin-containing monooxygenase 3 gene and essential hypertension: the joint effect of polymorphism E158K and cigarette smoking on disease susceptibility. Int J Hypertens. 2014;2014:1–5.
   Google Scholar
• Poetsch M, Czerwinski M, Wingenfeld L, et al. A common FMO3 polymorphism may amplify the effect of nicotine exposure in sudden infant death syndrome (SIDS). Int J Legal Med. 2010;124(4):301–306.
   PubMed Web of Science ®Google Scholar
• Teitelbaum AM, Murphy SE, Akk G, et al. Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. Pharmacogenomics J. 2017;1–8.
   Google Scholar
• Saccone SF, Saccone NL, Swan GE, et al. Systematic biological prioritization after a genome-wide association study: an application to nicotine dependence. Bioinformatics. 2008;24(16):1805–1811.
   PubMed Web of Science ®Google Scholar
• Xu M, Bhatt DK, Yeung CK, et al. Genetic and non-genetic factors associated with protein abundance of flavin-containing monooxygenase 3 in human liver. J Pharmacol Exp Ther. 2017;363(2):265–274.
   PubMed Web of Science ®Google Scholar
• Bloom AJ, Murphy SE, Martinez M, et al. Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption. Pharmacogenet Genomics. 2013;23:62–68.
   PubMedGoogle Scholar
• Hinrichs AL, Murphy SE, Wang JC, et al. Common polymorphisms in FMO1 are associated with nicotine dependence. Pharmacogenet Genomics. 2011;21:397–402.
   PubMed Web of Science ®Google Scholar
• Dolphin CT, Beckett DJ, Janmohamed A, et al. The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J Biol Chem. 1998;273(46):30599–30607.
   PubMed Web of Science ®Google Scholar
• Bloom AJ, von Weymarn LB, Martinez M, et al. The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans. Pharmacogenet Genomics. 2013;23(12):706–716.
   PubMed Web of Science ®Google Scholar
• Berg JZ, Von Weymarn LB, Thompson EA, et al. UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1423–1431.
   PubMed Web of Science ®Google Scholar
• Berg JZ, Mason J, Boettcher AJ, et al. Nicotine metabolism in african americans and european americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J Pharmacol Exp Ther. 2010;332(1):202–209.
   PubMed Web of Science ®Google Scholar
• Patel YM, Stram DO, Wilkens LR, et al. The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev. 2015;24(1):119–127.
   PubMed Web of Science ®Google Scholar
• Chen G, Giambrone NE Jr, Dluzen DF, et al. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of UGT2B10 and UGT2B17 knock-out polymorphisms. Cancer Res. 2010;70(19):7543–7552.
   PubMed Web of Science ®Google Scholar
• Wassenaar CA, Conti DV, Das S, et al. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidemiol Biomarkers Prev. 2015;24(1):94–104.
   PubMed Web of Science ®Google Scholar
• Kaivosaari S, Finel M, Koskinen M. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica. 2011;41(8):652–669.
   PubMed Web of Science ®Google Scholar
• Ghotbi R, Mannheimer B, Aklillu E, et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol. 2010;66(5):465–474.
   PubMed Web of Science ®Google Scholar
• Urakami Y, Okuda M, Masuda S, et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998;287(2):800–805.
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Pilot programs seek to integrate genomic data into practice. JAMA. 2017 Aug;1(318):410–412.
   Google Scholar